Maillere; Bernard

Patent Applications and Registrations

Patent applications and USPTO patent grants for Maillere; Bernard.The latest application filed is for "immunogenic peptides of the cyclin b1 tumor antigen".

Company Profile

1.10.16

Maillere; Bernard - Versailles FR
MAILLERE; Bernard - Gif Sur Yvette FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Immunogenic peptides of the cyclin B1 tumor antigen Grant 10,550,166 - Maillere , et al. Fe	2020-02-04
Immunogenic Peptides of the Cyclin B1 Tumor Antigen App 20180086804 - Maillere; Bernard ; et al.	2018-03-29
Method for real-time measurement of the individual secretions of a cell Grant 9,841,429 - Livache , et al. December 12, 2	2017-12-12
HB-EGF inhibitor derived from the R domain of diphtheria toxin for the treatment of diseases associated with the activation of the HB-EGF/EGFR pathway Grant 9,758,552 - Gillet , et al. September 12, 2	2017-09-12
CD4+ T survivin epitopes and uses thereof Grant 9,687,539 - Wang , et al. June 27, 2	2017-06-27
Immunogenic Peptides Of The Cyclin B1 Tumor Antigen App 20160257727 - Maillere; Bernard ; et al.	2016-09-08
Hb-egf Inhibitor Derived From The R Domain Of Diphtheria Toxin For The Treatment Of Diseases Associated With The Activation Of The Hb-egf/egfr Pathway App 20150051146 - Gillet; Daniel ; et al.	2015-02-19
CD4+ T Survivin Epitopes and Uses Thereof App 20150050304 - Wang; XiaoFei ; et al.	2015-02-19
Hla Peptide Therapy App 20140295550 - BALL; Simon ; et al.	2014-10-02
HLA peptide therapy Grant 8,715,680 - Ball , et al. May 6, 2	2014-05-06
Method for Real-Time Measurement of the Individual Secretions of a Cell App 20130137085 - LIVACHE; Thierry ; et al.	2013-05-30
Method for Evaluating The Immunogenicity of Proteins App 20110275098 - Maillere; Bernard ; et al.	2011-11-10
Immunogenic Peptides Derived from the Midkine Protein, as an Anticancer Vaccine App 20110159022 - Kerzerho; Jerome ; et al.	2011-06-30
Method Of Selecting Hla-dp4 Ligands And The Applications Thereof App 20100324829 - MAILLERE; Bernard ; et al.	2010-12-23
Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof App 20100203080 - Maillere; Bernard ; et al.	2010-08-12
Method of selecting HLA-DP4 ligands and the applications thereof Grant 7,718,575 - Maillere , et al. May 18, 2	2010-05-18
T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof App 20090130134 - Pancre; Veronique ; et al.	2009-05-21
Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof Grant 7,488,791 - Maillere , et al. February 10, 2	2009-02-10
Cd4+ Survivin Epitopes and Uses Thereof App 20090004214 - Wang; XiaoFei ; et al.	2009-01-01
Mixture of peptides from c and ns3 proteins of the hepatitis c virus and applications thereof App 20060110401 - Maillere; Bernard ; et al.	2006-05-25
Method of selecting hla-dp4 ligands and the applications thereof App 20050059107 - Maillere, Bernard ; et al.	2005-03-17
Mixture of peptides originating from a Nef protein and applications thereof App 20040115622 - Maillere, Bernard ; et al.	2004-06-17
Peptides and proteins for desensitizing subjects allergic to bee venom and compositions containing same Grant 6,649,166 - Maillere , et al. November 18, 2	2003-11-18

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.